Assessment of Fibrinolytic Activity by Measuring the Lysis Time of a Tissue Factor-induced Clot: A Feasibility Evaluation

Abstract

A clot lysis time assay in which a tissue factor—induced fibrin clot is lysed by exogenously added tissue plasminogen activator has been recently reported. We evaluated the feasibility of clot lysis time in a routine hemostasis laboratory, and its correlation with thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels and changes with aging in 185 healthy participants. Clot lysis time was assessed by monitoring changes in turbidity during clot formation and subsequent lysis using a computerized kinetic spectrophotometric microtiter plate. After preliminary experiments, 100 and 160 ng/mL tissue plasminogen activator concentrations were chosen for the study. Clot lysis time was calculated by a new mathematical analysis of the lysis curve based on discrete derivative. Clot lysis time, thrombin activatable fibrinolysis inhibitor, and plasminogen activator inhibitor-1 plasma levels showed a normal distribution. For both concentrations of tissue plasminogen activator, clot lysis time progressively increased with increase in age (P < .0001) and was significantly correlated with thrombin activatable fibrinolysis inhibitor antigen, thrombin activatable fibrinolysis inhibitor activity, and plasminogen activator inhibitor-1 antigen (at least P < .01). During linear regression analysis, thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 antigen were found to significantly influence clot lysis time (at least P < .01). Clot lysis time determination has a good laboratory performance. Our new method of calculation is independent of the time of reading and allows a more accurate and consistent detection of both short and prolonged lysis times. Our data suggest the feasibility of the use of this test in the work of routine hemostasis laboratory.

Keywords

clot lysis time fibrinolysis t-Pa TAFI PAI-1 antigen

References

Mutch NJ , Thomas L. , Moore NR , Lisiak KM , Booth NA TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J. Thromb Haemost. 2007;5:812-817.

Prins MH , Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med. 1991;151:1721-1731.

Smith AA , Jacobson LJ , Miller BI , Hathaway WE , Manco-Johnson MJ A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res. 2003;112:329-337.

Lisman T. , de Groot PG , Meijers JC , Rosendaal FR Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis . Blood. 2005;105:1102-1105.

Meltzer ME , Lisman T. , Doggen CJ , de Groot PG , Rosendaal FR Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous Thrombosis. PLoS. Med . 2008;5:e97.

Lisman T. , Leebeek FW , Mosnier LO , et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology . 2001;121:131-139.

Von dem Borne PA , Bajzar L. , Meijers JC , Nesheim ME , Bouma BN Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997;99:2323-2327.

Mosnier LO , Lisman T. , Van den Berg HM , Nieuwenhuis HK , Meijers JCM , Bouma BN The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost . 2001;86:1035-1039.

Lisman T. , Mosnier LO , Lambert T. , Mauser-Bunschoten EP , Meijers JC , Nieuwenhuis HK , et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. Blood. 2002;99:175-179.

10.

Colucci M. , Binetti BM , Branca MG , et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology. 2003;38:230-237.

11.

Klement P. , Liao P. , Bajzar L. A novel approach to arterial thrombolysis. Blood. 1999;94:2735-2743.

12.

Stromqvist M. , Schatteman K. , Leurs J. , et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost. 2001;85:12-17.

13.

Colucci M. , Binetti BM , Tripodi A. , Chantarangkul V. , Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood . 2004;103:2157-2161.

14.

Gentleman RC , Carey VJ , Bates DM , et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol . 2004;5:R80.

15.

Frère C. , Tregouet DA , Morange PE , et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study. Blood. 2006 ;108:1562-1568.

16.

Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol. 2006;60:144-151.

17.

Lahlou-Laforet K. , Alhenc-Gelas M. , Pornin M. , et al. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease . Am J Cardiol. 2006;97:1287-1291.

18.

Asselbergs FW , Williams SM , Hebert PR , et al. Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. J Thromb Haemost. 2007;5: 313-320.

19.

Chetaille P. , Alessi MC , Kouassi D. , Morange PE , Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb. Haemost. 2000;83:902-905.

20.

Juhan-Vague I. , Renucci JF , Grimaux M. , et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156-2161.

21.

Mosnier LO , von dem Borne PA , Meijers JC , Bouma BN Plasma TAFI levels influence the CLT in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost . 1998;80: 829-835.